A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein

The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed to safeguard against emerging variants and future pandemics. We used mRNA di...

Full description

Saved in:
Bibliographic Details
Published in:bioRxiv 2022-11
Main Authors: Thijssen, Vito, Hurdiss, Daniel L, Debski-Antoniak, Oliver J, Spence, Matthew A, Franck, Charlotte, Alexander, Norman, Aggarwal, Anupriya, Mokiem, Nadia J, David A A Van Dongen, Vermeir, Stein W, Liu, Minglong, Chatziandreou, Marianthi, Donselaar, Tim, Du, Wenjuan, Drulyte, Ieva, Bosch, Berend Jan, Snijder, Joost, Stuart Grant Turville, Payne, Richard J, Jackson, Colin J, Van Kuppeveld, Frank Jm, Seino A K Jongkees
Format: Article
Language:English
Subjects:
ACE2
Angiotensin-converting enzyme 2
Antiviral agents
COVID-19
Genetic code
mRNA
Pandemics
Patent applications
Peptide inhibitors
Peptides
Sarbecovirus
Severe acute respiratory syndrome coronavirus 2
Spike protein
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed to safeguard against emerging variants and future pandemics. We used mRNA display under a reprogrammed genetic code to find a spike-targeting macrocyclic peptide that inhibits SARS-CoV-2 Wuhan strain infection and also pseudoviruses containing spike proteins of SARS-CoV-2 variants or related sarbecoviruses. Structural and bioinformatic analyses reveal a conserved binding pocket between the receptor binding domain and other domains, distal to the ACE2 receptor-interaction site. Collectively, our data reveal a hitherto unexplored site of vulnerability in sarbecoviruses that can be targeted by peptides and potentially other drug-like molecules.Competing Interest StatementVT, DLH, FJMK and SAKJ are named inventors on a patent application that has been filed on 15 July 2022 entitled: Antiviral cyclic compounds (EP22185235; patent applicants: Universiteit Utrecht Holdings B.V. on behalf of Utrecht University). ID is an employee of Thermo Fisher Scientific. The remaining authors declare that they have no competing interests.Footnotes* Minor corrections to errors in figures and text, addition of accession numbers for structures and sequencing data
DOI:10.1101/2022.11.11.516114